Alecensa (Alectinib HCl) Patent Expiration, LOE Window & CMS Spending

Alecensa (Alectinib HCl) by Roche / Genentech: FDA Orange Book core substance LOE 2031-05-29 (last listed 2035-04-24), 0 AB generics, $295.4M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRoche / Genentech
FDA Application & PathwayN208434 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-05-29
Last Listed Patent or Exclusivity Date2035-04-24
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$295.4M
2024 Medicare Part D Spend$246.7M
2024 Medicaid Spend$48.7M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 16.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.